Malignant ascites is common in various types of cancers and is difficult to manage. Vascular endothelial growth factor (VEGF) has a pivotal role in malignant ascites. The matrix protein of vesicular ...
J Gastroenterol Hepatol. 2009;24(9):1494-1503. Transjugular Intrahepatic Portosystemic Shunting. Transjugular intrahepatic portosystemic shunting (TIPS) creates an iatrogenic intrahepatic shunt a ...
PREVIOUS studies have indicated that in patients with cirrhosis the presence or absence of ascites can be explained by a consideration of hydrostatic and osmotic forces, and a similar analysis can be ...
Hartveit, F. The growth of Ehrlich's ascites carcinoma in C3H mice and in mice of an unrelated closed colony. Variation in tumour growth, cytology and ascites ...
Ascites often develops as a complication of liver disease, causing fluid buildup in the abdominal cavity. Common treatments for ascites include reducing sodium intake, taking diuretics, and undergoing ...
Blocking the action of vascular endothelial growth factor (VEGF) with the new anti-VEGF drug aflibercept can curb the development of malignant ascites (excessive fluid in the abdomen), a common and ...
Ascites is a buildup of fluid in the abdomen. It can happen when the liver is not working properly. Fluid fills the space between the organs and the abdominal lining, leading to swelling and pain.
PREVIOUS studies have indicated that in patients with cirrhosis the presence or absence of ascites can be explained by a consideration of hydrostatic and osmotic forces, and a similar analysis can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback